This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Krauß, S. Articles by Schweiger, S. PubMed PubMed Citation Articles by Krauß, S. Articles by Schweiger, S.

Protein Phosphatase 2A and Rapamycin Regulate the Nuclear Localization and Activity of the Transcription Factor GLI3

¹ Charité University Hospital, Department of Dermatology and ² Max-Planck Institute for Molecular Genetics, Berlin, Germany; ³ Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, Innsbruck, Austria; and ⁴ Ninewells Hospital, Department of Neuroscience and Pathology, Scotland, United Kingdom

Requests for reprints: Rainer Schneider, Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, Peter-Mayr-Strasse 1a, 6020 Innsbruck, Austria. Phone: 0043-512-507-5273; Fax: 0043-512-507-96956; E-mail: rainer.schneider{at}uibk.ac.at.

Key Words: PP2A • mTORC1 • rapamycin • GLI3 • MID1

Gain-of-function alterations to the sonic hedgehog (SHH) signaling cascade have been found in a wide range of tumors. Three SHH effectors, GLI1, GLI2, and GLI3, regulate transcription of diverse genes involved in cell growth and cell proliferation. Here, we show that protein phosphatase 2A (PP2A), its regulatory subunit, 4, and rapamycin, an inhibitor of the mammalian target of rapamycin kinase complex 1 (mTORC1), regulate the nuclear localization and transcriptional activity of GLI3. An increase in PP2A activity or treatment with rapamycin leads to cytosolic retention of GLI3 and, consequently, reduced transcription of the GLI3 target gene and cell cycle regulator, cyclin D1. Conversely, inhibition of PP2A results in increased expression of cyclin D1. In summary, our findings reveal the existence of a hitherto unrecognized molecular cross-talk between the oncogenic SHH pathway and the tumor suppressor PP2A and suggest a novel mechanism underlying the anticancerogenic effects of rapamycin. [Cancer Res 2008;68(12):4658–65]